Matinas BioPharma Reports Positive Data From First Half Of EnACT Study - Quick Facts

Matinas BioPharma Holdings, Inc. (MTNB) reported positive efficacy and safety data from the first two cohorts of patients in the ongoing EnACT study of MAT2203 for the treatment of cryptococcal meningitis. In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.

The EnACT independent Data and Safety Monitoring Board completed a pre-specified review of available safety and efficacy data from Cohort 2 and recommended progression to the second half of the study.

Shares of Matinas BioPharma were up 9% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT